Abstract:In recent years, clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) protein have emerged as a revolutionary gene editing tool to treat inherited disorders affecting different organ systems, such as blood and muscles. Both hematological and neuromuscular genetic disorders benefit from genome editing approaches but face different challenges in their clinical translation. The ability of CRISPR/Cas9 technologies to modify hematopoietic stem cells ex vivo has greatly accelerated the development of genetic therapies for blood disorders. In the last decade, many clinical trials were initiated and are now delivering encouraging results. The recent FDA approval of Casgevy, the first CRISPR/Cas9-based drug for severe sickle cell disease and transfusion-dependent β-thalassemia, represents a significant milestone in the field and highlights the great potential of this technology. Similar preclinical efforts are currently expanding CRISPR therapies to other hematologic disorders such as primary immunodeficiencies. In the neuromuscular field, the versatility of CRISPR/Cas9 has been instrumental for the generation of new cellular and animal models of Duchenne muscular dystrophy (DMD), offering innovative platforms to speed up preclinical development of therapeutic solutions. Several corrective interventions have been proposed to genetically restore dystrophin production using the CRISPR toolbox and have demonstrated promising results in different DMD animal models. Although these advances represent a significant step forward to the clinical translation of CRISPR/Cas9 therapies to DMD, there are still many hurdles to overcome, such as in vivo delivery methods associated with high viral vector doses, together with safety and immunological concerns. Collectively, the results obtained in the hematological and neuromuscular fields emphasize the transformative impact of CRISPR/Cas9 for patients affected by these debilitating conditions. As each field suffers from different and specific challenges, the clinical translation of CRISPR therapies may progress differentially depending on the genetic disorder. Ongoing investigations and clinical trials will address risks and limitations of these therapies, including long-term efficacy, potential genotoxicity, and adverse immune reactions. This review provides insights into the diverse applications of CRISPR-based technologies in both preclinical and clinical settings for monogenic blood disorders and muscular dystrophy and compare advances in both fields while highlighting current trends, difficulties, and challenges to overcome.

[Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology]

CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia

CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for Transfusion-Dependent β-Thalassemia—CRISPR-Cas9 Gene Editing for β-Thalassemia

Progress of CRISPR-Cas9 in Treatment of β-thalassemia

Gene therapy and gene editing strategies in inherited blood disorders

CRISPR/Cas9 in the treatment of -thalassemia

β-Thalassemia gene editing therapy: Advancements and difficulties

CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments

Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight

[Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review]

CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

Therapeutic Gene Editing for Hemoglobinopathies

Development and application of CRISPR/Cas9 technologies in genomic editing.

CRISPR-Cas9 gene editing technology in human gene therapy: the new realm of medicine

CRISPR/Cas9 therapeutics: progress and prospects

The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

Therapeutic applications of CRISPR/Cas9 system in gene therapy

The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies

CRISPR/Cas9 Mechanism and Applications Progression

Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics